Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Muñoz, Abhinav Deol, David B. Miklos, Nancy L. Bartlett, Ira Braunschweig, Yizhou Jiang, Jaeyeon Kim, Lianqing Zheng, John M. Rossi, Frederick L. Locke
Abstract
Neelapu and colleagues report a post hoc subgroup analysis from the ZUMA-1 trial of chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B cell lymphoma. In comparison with younger patients, those ≥65 years old have similar rates of complete response and durable response at 2 years, but higher rates of neurological toxicity.
Topics & Concepts
MedicineChimeric antigen receptorRefractory (planetary science)LymphomaInternal medicineOncologyImmunologyImmunotherapyCancerBiologyAstrobiologyCAR-T cell therapy researchIntegrated Circuits and Semiconductor Failure AnalysisLymphoma Diagnosis and Treatment